Apellis Pharmaceuticals, Inc. (APLS) Q2 2019 Earnings Results

Apellis Pharmaceuticals Misses on EPS, Stock Down 3.22%

The earnings report indicates that Apellis Pharmaceuticals is still in a challenging financial position, as evidenced by the negative EPS. The stock reacted negatively, dropping 3.22%, likely due to the lack of revenue information and guidance. Investors may be concerned about the company's future performance without clear targets or metrics.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-1.12	N/A	N/A
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management acknowledged the challenges faced in the quarter. They emphasized their commitment to ongoing projects without offering specific guidance.

Management did not provide specific revenue figures or guidance for the upcoming quarters.

The company is focused on advancing its pipeline despite the current financial results.

Apellis Pharmaceuticals Misses on EPS, Stock Down 3.22%

Key numbers

Management commentary

Apellis Pharmaceuticals, Inc.

More earnings this week

Apellis Pharmaceuticals Misses on EPS, Stock Down 3.22%

Key numbers

Management commentary